Skip to main content
Clinical Trials/CTRI/2011/12/002202
CTRI/2011/12/002202
Completed
Phase 4

Comparative Evaluation of Efficacy and Tolerability of Euphorbia Prostrata Extract in treatment of first & second degree hemorrhoids

Panacea Biotec Limited0 sites100 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- first degree external or internal heamorrhoids
Sponsor
Panacea Biotec Limited
Enrollment
100
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects with diagnosis of acute uncomplicated first degree external or internal hemorrhoids with active bleeding without infection and prolapse.
  • Provided written informed consent.

Exclusion Criteria

  • Presence of infection of anorectal region.
  • Presence of other rectal pathology like anal fissure, rectal prolapse, ischiorectal abscess, anorectal fistula, or rectal polyp.
  • Subjects with known hepatic or kidney diseases.
  • Patients with known hypersensitivity to ingredients of study or comparator treatments
  • Clinically significant co\-morbid condition other than bleeding piles that could directly affect the efficacy \& tolerability outcome of the study.
  • Donated blood or plasma or participated in another clinical study with an investigational agent within 4 weeks preceding to enrollment.
  • H/O drug/alcohol abuse.
  • Pregnant and lactating women.
  • Any other condition that, in the opinion of the investigator, does not justify the inclusion of the subject in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials